The potential role of recombinant HGF in the treatment of NASH was also demonstrated by Yang et al., who could show that mice which were fed a choline-deficient amino acid defined diet (CDAA) display improved inflammation, steatosis and lipid profile when treated with recombinant feline HGF (51). This evidence concerns the gene HGF and metabolic dysfunction-associated steatohepatitis.